XNAS
TWST
Market cap9.47bUSD
Oct 08, Last price
152.05USD
1D
-2.31%
1Q
67.76%
IPO
978.37%
Name
Twist Bioscience Corp
Chart & performance
P/E
—
P/S
25.14
EPS
—
Div yield, %
—
Shrs. gr., 5y
8.82%
Rev. gr., 5y
33.11%
Revenues
377m
+20.32%
Net income
-78m
L-62.79%
CFO
-48m
L-25.69%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Key people
Chairman of the Board, President, Chief Executive Officer · since 2018
Chief Financial Officer · since 2018
Mark Daniels
Senior Vice President, Secretary, Chief Legal Officer, Chief Ethics and Compliance Officer · since 2018
Martin Kunz
Senior Vice President - Operation · since 2019
Bill James Peck
Chief Technology Officer · since 2013
Paula Green
Vice President of Human Resources · since 2016
Lead Independent Director · since 2018
Nicolas Barthelemy
Director · since 2019
Jan Johannessen
Director · since 2018
Independent Director · since 2019
Independent Director · since 2013
Robert Ragusa
Independent Director · since 2017
Mai Xiaoying
Independent Director · since 2018
Legal address
C/O Incorporating Services Ltd
3500 South Dupont Highway
Dover, DE 19901
US
3500 South Dupont Highway
Dover, DE 19901
US
Headquarters
455 Mission Bay Boulevard South
Suite 545
San Francisco, CA 94158
US
Suite 545
San Francisco, CA 94158
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||